Document Detail


The biomarker is not the end.
MedLine Citation:
PMID:  21888986     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
As drug discovery and translational scientists think about using stratification with biomarkers to improve the chances of getting medicines to patients, several areas of expertise need to be considered. These include analytical validation, clinical validation, regulatory affairs and intellectual property. Getting the right input from the right expert at the right time can make or break an effort to bring a biomarker-based companion diagnostic successfully into clinical practice.
Authors:
Michael Nohaile
Related Documents :
16427536 - Anesthetic implications of traumatic pulmonary hernia repair.
20225986 - Active versus expectant management for preterm prelabor rupture of membranes at 34-36 w...
21221306 - Moderating benzodiazepine use in the elderly: curbing physicians' prescribing practices.
20678106 - Aortic complications of giant cell arteritis: a diagnostic and management dilemma.
19781366 - Modern use of chinese herbal formulae from shang-han lun.
3973846 - Defaulted appointments in general practice.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-24
Journal Detail:
Title:  Drug discovery today     Volume:  -     ISSN:  1878-5832     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-9-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Ltd.
Affiliation:
Novartis Pharma AG, CHBS, WSJ-760CH, 4002 Basel, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The 14-3-3 proteins in regulation of cellular metabolism.
Next Document:  Drug-diagnostic co-development: how to harness the value.